Rapamycin is increasingly prescribed off-label by anti-aging physicians based on animal studies and very limited human data (even including the relatively recent crowdfunded PEARL trial) for it to improve late-life metabolism. Rapamycin and other mTOR inhibitors are calorie restriction mimetics, provoking a greater level of autophagy to improve cell maintenance. In mice, rapamycin results in a ~20-25% increase in life span, a sizable fraction of the ~40% that is possible via calorie restriction. We know that human calorie restriction is beneficial to health in many ways, but doesn't add more than a few years to life span - while no actual assessment has been carried out, it would be hard for an effect of more than five years or so to remain hidden from interested epidemiologists and scientists across the course of history.
Rapamcyin can be prescribed off-label because it has long been used as an immunosuppressant drug at much higher doses than the anti-aging use, and the safety profile for that use is well mapped. The drug has existed for long enough that it is now generic, outlasted its patent protection. Generic drugs tend to see little further formal clinical trial activity because they cannot produce enough income to sustain the high costs imposed by regulatory authorities. That doesn't stop academics from sometimes managing to obtain enough funding to explore unanswered questions, however.
While enough people are presently using rapamycin off-label at anti-aging doses for a recent study to find more than 300 individuals who were willing to provide information on their rapamycin use, in general this sort of use generates next to no actually useful, robust data. To obtain that data clinical trials of some sort, at the very least run by a reputable organization, remain needed. At present, there is no great consensus that any of the present range of anti-aging doses used in the community are in fact the optimal dose for humans. There are also remaining questions as to the dose at which undesirable immunosuppressive or hyperglycemic effects begin to emerge, and how prevalent they are. So it is good to see that an academic group has found the funds needed to run an initial set of trials aimed at answering these questions.
Large rapamycin clinical trial launches
Researchers are launching a multi-phase clinical study to better understand the biological effects of rapamycin in older adults. The study reflects a shift toward evidence-based dosing, safety, and long-term outcomes rather than off-label and speculative use of rapamycin. "Rapamycin is widely discussed in popular culture as a longevity drug. But there's a difference between something that is biologically plausible and something that has been rigorously tested in people."
The current study is structured as a series of interconnected sub-studies, each designed to answer a specific question. The translational pipeline will move from biological benchmarks to long-term clinical observation. The first sub-study establishes a reference point by examining immune and metabolic markers in younger adults. These measurements help define what "optimal" function looks like before aging-related changes begin.
The second sub-study will determine the optimal rapamycin dosage for older adults that will safely bring them back to the optimal functioning seen in the younger population. The dosage used for transplant patients may be too high for safe use in generally healthy older adults, so the scientists are testing different dosing schedules to determine how much rapamycin is needed to reach biological targets without negative side effects. "This phase is about precision. We're asking how much drug it actually takes to achieve a desired biological effect, not more than that."
The third sub-study is the largest cohort and will run the longest. It is a randomized, placebo-controlled clinical trial involving approximately 84 older adults who will receive either daily rapamycin, intermittent dosing, or a placebo. Participants will be treated for six months and followed for an additional six months to assess both short-term effects and sustained effects after treatment ends.
View the full article at FightAging
